We are live on ! Find out more
VC

Vivo Capital Portfolio holdings

AUM $1.2B
1-Year Est. Return 911.44%
This Fund
S&P 500
This Quarter Est. Return
-11.57%
1 Year Est. Return
+911.44%
3 Year Est. Return
+7,373.93%
5 Year Est. Return
+10,475.15%
10 Year Est. Return
+136,503.27%
AUM
$1.66B
AUM Growth
-$569M
Cap. Flow
-$51.7M
Cap. Flow %
-3.12%
Top 10 Hldgs %
63.62%
Holding
67
New
7
Increased
4
Reduced
8
Closed
12

Top Buys

Rank Stock Value
1
VTYX
Ventyx Biosciences
VTYX
+$33.9M
2
IOBT
IO Biotech
IOBT
+$29.1M
3
RLMD icon
Relmada Therapeutics
RLMD
+$19.6M
4
UTRS
Minerva Surgical, Inc. Common Stock
UTRS
+$15.8M
5
OLMA icon
Olema Pharmaceuticals
OLMA
+$9.34M

Top Sells

Rank Stock Value
1
ASND icon
Ascendis Pharma A/S
ASND
+$47.3M
2
KDMN
Kadmon Holdings, Inc.
KDMN
+$37.3M
3
LEGN icon
Legend Biotech
LEGN
+$12.4M
4
CRIS icon
Curis
CRIS
+$12.2M
5
AUPH icon
Aurinia Pharmaceuticals
AUPH
+$11.1M

Sector Composition

Rank Sector Weight
1 Healthcare 86.32%
2 Financials 9.88%
3 Materials 3.8%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ELEV
51
DELISTED
Elevation Oncology
ELEV
$2.99M 0.18%
496,844
+1
+0% +$7
ZGNX
52
DELISTED
Zogenix, Inc.
ZGNX
$1.71M 0.1%
105,000
– –
DTIL icon
53
Precision BioSciences
DTIL
$192M
$1.04M 0.06%
4,675
– –
MTCR
54
DELISTED
Metacrine, Inc. Common Stock
MTCR
$99K 0.01%
146,426
– –
EIGR
55
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
$22K ﹤0.01%
139
-15,514
-99% -$3M
ARQT icon
56
Arcutis Biotherapeutics
ARQT
$3.31B
– –
-433,585
Closed -$10.4M
AUPH icon
57
Aurinia Pharmaceuticals
AUPH
$1.95B
– –
-500,732
Closed -$11.1M
CRIS icon
58
Curis
CRIS
$8.83M
– –
-3,884
Closed -$12.2M
CRNX icon
59
Crinetics Pharmaceuticals
CRNX
$8.91B
– –
-517,280
Closed -$10.9M
KURA icon
60
Kura Oncology
KURA
$812M
– –
-525,262
Closed -$9.84M
PASG icon
61
Passage Bio
PASG
$14.8M
– –
-26,963
Closed -$5.37M
SNDX icon
62
Syndax Pharmaceuticals
SNDX
$1.75B
– –
-320,000
Closed -$6.12M
TXG icon
63
10x Genomics
TXG
$6.02B
– –
-14,798
Closed -$2.15M
VALN
64
Valneva
VALN
$534M
– –
-200,000
Closed -$6.28M
ORTX
65
DELISTED
Orchard Therapeutics plc American Depositary Shares
ORTX
– –
-132,574
Closed -$3.05M
TCDA
66
DELISTED
Tricida, Inc. Common Stock
TCDA
– –
-167,863
Closed -$779K
KDMN
67
DELISTED
Kadmon Holdings, Inc.
KDMN
– –
-4,283,014
Closed -$37.3M
1 2
3

Similar funds

SGDR
SPX Gestao de Recursos Rio De Janeiro, Brazil $1.2B AUM 59.05% 1-Year Est. Return
FCCPG
FountainVest China Capital Partners GP3 Grand Cayman, Cayman Islands $1.2B AUM 6.95% 1-Year Est. Return
AIM
Anchor Investment Management Columbia, South Carolina $1.2B AUM 17.33% 1-Year Est. Return
SC
Shay Capital New York $1.2B AUM 37.47% 1-Year Est. Return
MB
MidFirst Bank Oklahoma City, Oklahoma $1.21B AUM
CCM
Condor Capital Management Martinsville, New Jersey $1.2B AUM 13.18% 1-Year Est. Return
TIM
Tortoise Investment Management White Plains, New York $1.21B AUM 13.04% 1-Year Est. Return
CS
Central Securities New York $1.21B AUM 19.91% 1-Year Est. Return

Vivo Capital's Q4 2021 Portfolio in Review

As of Q4 2021, Vivo Capital held 67 positions worth $1.66B, down 26% from $2.23B the previous quarter. Its ten largest holdings account for 64% of the portfolio.

Vivo Capital withdrew a net $51.7M in Q4 2021, closing 12 positions and reducing 8 holdings. Its most notable exit was Kadmon Holdings, Inc., an estimated $37.3M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 86% of assets, up from 86% a quarter earlier, followed by Financials and Materials.

Against the trend, Vivo Capital opened a new position in Ventyx Biosciences worth $35.6M.

  • Vivo Capital's largest Q4 2021 buy was Ventyx Biosciences: 1,791,275 shares worth $35.6M.
  • Vivo Capital added most to Olema Pharmaceuticals in Q4 2021, an estimated $9.34M increase.
  • Vivo Capital's biggest Q4 2021 reduction was Ascendis Pharma A/S, cutting an estimated $47.3M.
  • Vivo Capital fully exited Kadmon Holdings, Inc. in Q4 2021, selling an estimated $37.3M.
  • Vivo Capital's ten largest holdings make up 64% of its $1.66B portfolio in Q4 2021.
  • Vivo Capital opened 7 new positions and closed 12 in Q4 2021.
  • Vivo Capital's portfolio value fell 26% quarter-over-quarter to $1.66B.

Based on Vivo Capital's 13F filing for Q4 2021, filed 11 Feb 2022.